Satoshi Saito, Keisuke Suzuki, Ryo Ohtani, Takakuni Maki, Hisatomo Kowa, Hisatsugu Tachibana, Kazuo Washida, Nobuya Kawabata, Toshiki Mizuno, Rie Kanki, Shinji Sudoh, Hiroshi Kitaguchi, Katsuro Shindo, Akihiro Shindo, Nobuyuki Oka, Keiichi Yamamoto, Fumihiko Yasuno, Chikage Kakuta, Ryosuke Kakuta, Yumi Yamamoto, Yorito Hattori, Yukako Takahashi, Yuriko Nakaoku, Shuichi Tonomura, Naoya Oishi, Toshihiko Aso, Akihiko Taguchi, Tatsuo Kagimura, Shinsuke Kojima, Masanori Taketsuna, Hidekazu Tomimoto, Ryosuke Takahashi, Hidenao Fukuyama, Kazuyuki Nagatsuka, Haruko Yamamoto, Masanori Fukushima, Masafumi Ihara
IMPORTANCE: Recent evidence indicates the efficacy of β-amyloid immunotherapy for the treatment of Alzheimer disease, highlighting the need to promote β-amyloid removal from the brain. Cilostazol, a selective type 3 phosphodiesterase inhibitor, promotes such clearance by facilitating intramural periarterial drainage. OBJECTIVE: To determine the safety and efficacy of cilostazol in mild cognitive impairment. DESIGN, SETTING, AND PARTICIPANTS: The COMCID trial (A Trial of Cilostazol for Prevention of Conversion from Mild Cognitive Impairment to Dementia) was an investigator-initiated, double-blind, phase 2 randomized clinical trial...
December 1, 2023: JAMA Network Open